Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

IMMUNOCORE HOLDINGS PLC

(IMCR)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/18/2021 10/19/2021 10/20/2021 10/21/2021 10/22/2021 Date
37.61(c) 38.02(c) 39.85(c) 37.74(c) 37.81(c) Last
110 620 46 286 65 837 39 961 94 108 Volume
-1.03% +1.09% +4.81% -5.29% +0.19% Change
More quotes
Estimated financial data (e)
Sales 2021 24,3 M 33,4 M 33,4 M
Net income 2021 -137 M -188 M -188 M
Net cash position 2021 163 M 224 M 224 M
P/E ratio 2021 -8,67x
Yield 2021 -
Sales 2022 28,8 M 39,6 M 39,6 M
Net income 2022 -157 M -216 M -216 M
Net cash position 2022 201 M 276 M 276 M
P/E ratio 2022 -8,20x
Yield 2022 -
Capitalization 1 204 M 1 656 M 1 655 M
EV / Sales 2021 42,8x
EV / Sales 2022 34,8x
Nbr of Employees 291
Free-Float 73,4%
More Financials
Company
Immunocore Holdings plc, formerly Immunocore Holdings Ltd, is a late-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies called Immune mobilizing monoclonal TCRs Against X disease (ImmTAX) designed to treat diseases, including cancer, infectious and autoimmune. The Company is developing a deep pipeline in multiple therapeutic areas, including five clinical stage... 
More about the company
Ratings of Immunocore Holdings plc
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about IMMUNOCORE HOLDINGS PLC
10/18IMMUNOCORE : to Collaborate With Medison Pharma to Expand Reach of Metastatic Uveal Melano..
MT
10/18IMMUNOCORE : and Medison Pharma Partner for Future Commercialization of Tebentafusp in Can..
GL
10/18Immunocore and Medison Pharma Partner for Future Commercialization of Tebentafusp in Ca..
GL
10/18Immunocore and Medison Pharma Partner for Future Commercialization of Tebentafusp in Ca..
CI
09/22IMMUNOCORE : announces publication of phase 3 data comparing tebentafusp with investigator..
AQ
09/22Immunocore Announces Publication of Phase 3 Data Comparing tebentafusp with Investigato..
CI
09/21IMMUNOCORE : Dr. Carolin Barth Joins MiroBio as CEO to Lead Precision Immunology Company F..
AQ
09/20IMMUNOCORE : Reports Data From Phase 2 Trial of Tebentafusp
MT
09/20Immunocore presents data at the European Society for Medical Oncology (ESMO) Congress 2..
GL
09/20Immunocore Presents Data At the European Society for Medical Oncology Congress 2021 Dem..
CI
09/13IMMUNOCORE : Announces Upcoming Presentations at the European Society for Medical Oncology..
AQ
09/10Immunocore to present at upcoming investor conferences
GL
09/08IMMUNOCORE : Tebentafusp Accepted for Marketing Authorization Review by UK Regulator
MT
09/08Immunocore Announces UK's Medicines and Healthcare Products Regulatory Agency (MHRA) Ac..
GL
09/08Immunocore Announces UK’s Medicines and Healthcare Products Regulatory Agency Accepts M..
CI
More news
News in other languages on IMMUNOCORE HOLDINGS PLC
10/18Immunocore va collaborer avec Medison Pharma pour étendre la portée du traitement du mé..
09/20Immunocore présente les résultats de l'essai de phase 2 sur le Tebentafusp
09/01MIDDAY BRIEFING - Unternehmen und Märkte -2-
09/01PTA-NEWS : Medigene AG: Medigene verlängert Finanzierungsreichweite bis in das erste Quart..
More news
Analyst Recommendations on IMMUNOCORE HOLDINGS PLC
More recommendations
Chart IMMUNOCORE HOLDINGS PLC
Duration : Period :
Immunocore Holdings plc Technical Analysis Chart | IMCR | US45258D1054 | MarketScreener
Technical analysis trends IMMUNOCORE HOLDINGS PLC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 2 749,62 GBX
Average target price 3 840,58 GBX
Spread / Average Target 39,7%
EPS Revisions
Managers and Directors
Bahija Jallal Chief Executive Officer & Director
Brian R. DiDonato Chief Financial Officer & Head-Strategy
David Berman Head-Research & Development
Roy Steven Herbst Non-Executive Director
John Irving Bell Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
IMMUNOCORE HOLDINGS PLC0.00%1 656
MODERNA, INC.212.57%131 807
LONZA GROUP AG32.74%61 177
IQVIA HOLDINGS INC.43.38%49 076
SEAGEN INC.-2.12%31 189
CELLTRION, INC.-38.86%25 455